Bausch Health Cos (NYSE:BHC) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Bausch Health Cos (NYSE:BHC) from a buy rating to a strong-buy rating in a research note issued to investors on Saturday morning.

Other equities analysts have also recently issued research reports about the company. Jefferies Financial Group upgraded Bausch Health Cos to a “hold” rating in a report on Wednesday, July 22nd. Zacks Research downgraded shares of Bausch Health Cos from a “hold” rating to a “strong sell” rating in a research report on Friday, July 24th. Weiss Ratings downgraded shares of Bausch Health Cos from a “sell (d)” rating to a “sell (d-)” rating in a research report on Monday, May 4th. Finally, Royal Bank Of Canada reduced their price objective on shares of Bausch Health Cos from $10.00 to $9.00 and set a “sector perform” rating on the stock in a research note on Monday, April 27th. Five research analysts have rated the stock with a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Reduce” and a consensus price target of $8.00.

Bausch Health Cos Stock Up 1.7%

NYSE:BHC opened at $7.01 on Friday. Bausch Health Cos has a 12-month low of $4.33 and a 12-month high of $8.69. The company has a quick ratio of 1.08, a current ratio of 1.44 and a debt-to-equity ratio of 54.68. The firm has a market capitalization of $2.62 billion, a P/E ratio of -2.37 and a beta of 0.38. The stock’s fifty day simple moving average is $5.02 and its 200-day simple moving average is $5.45.

Bausch Health Cos (NYSE:BHC) last announced its quarterly earnings data on Wednesday, July 29th. The company reported $1.26 EPS for the quarter, topping analysts’ consensus estimates of $0.96 by $0.30. The business had revenue of $2.83 billion during the quarter, compared to analysts’ expectations of $2.59 billion. Bausch Health Cos had a negative return on equity of 561.95% and a negative net margin of 10.12%. Equities research analysts expect that Bausch Health Cos will post 4.05 earnings per share for the current year.

Insiders Place Their Bets

In other news, Director Frank D. Lee sold 24,456 shares of the firm’s stock in a transaction that occurred on Tuesday, May 19th. The shares were sold at an average price of $5.43, for a total transaction of $132,796.08. Following the completion of the transaction, the director directly owned 49,339 shares of the company’s stock, valued at $267,910.77. This trade represents a 33.14% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 20.67% of the stock is currently owned by company insiders.

Institutional Trading of Bausch Health Cos

A number of institutional investors have recently made changes to their positions in the business. Norges Bank acquired a new position in shares of Bausch Health Cos during the 4th quarter worth approximately $25,592,000. MUFG Securities EMEA plc acquired a new stake in shares of Bausch Health Cos in the 2nd quarter valued at approximately $22,644,000. Paulson & CO. Inc. boosted its holdings in shares of Bausch Health Cos by 3.5% in the 4th quarter. Paulson & CO. Inc. now owns 73,255,869 shares of the company’s stock valued at $509,128,000 after buying an additional 2,500,000 shares during the last quarter. Royal Bank of Canada boosted its holdings in shares of Bausch Health Cos by 24.9% in the 1st quarter. Royal Bank of Canada now owns 11,363,498 shares of the company’s stock valued at $61,362,000 after buying an additional 2,262,894 shares during the last quarter. Finally, Goldman Sachs Group Inc. grew its stake in shares of Bausch Health Cos by 65.7% in the fourth quarter. Goldman Sachs Group Inc. now owns 5,143,641 shares of the company’s stock valued at $35,748,000 after buying an additional 2,038,813 shares in the last quarter. Institutional investors own 78.65% of the company’s stock.

Bausch Health Cos Company Profile

Bausch Health Cos Inc, formerly known as Valeant Pharmaceuticals International, is a global specialty pharmaceutical company headquartered in Laval, Quebec, Canada. The company operates through two primary segments: Ophthalmology, led by its Bausch + Lomb franchise, and Diversified Brands, which encompasses prescription dermatology, gastrointestinal, neurology and branded pharmaceutical products. Bausch Health develops, manufactures and markets a range of therapeutic and over-the-counter offerings designed to address conditions such as cataracts, dry eye, glaucoma, acne, rosacea, migraine and gastrointestinal disorders.

The Ophthalmology segment under the Bausch + Lomb name provides products for eye health, including prescription drops, contact lens care solutions, intraocular lenses, surgical instruments and diagnostic devices.